News 
Market Data 
Discover
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Houston we have $BIXT lift off. Telemetry confirms we are about to pass Mach 1...
$ land in sight
BIXT, today, here, right now: https://ih.advfn.com/stock-market/USOTC/bioxytran-qb-BIXT/stock-news/89777698/current-report-filing-8-k
Item 8.01 Other Events.
On September 7, 2022, Bioxytran, Inc. (“Bioxytran” or the “Company”) registered, in India, a fully owned subsidiary, Pharmalectin India Private Limited, (the “Subsidiary”). The purpose of the Subsidiary is to be the sponsor of the Company’s clinical trials and commercialize the Company’s products, in India. The Subsidiary’s Certificate of Registration is filed as Exhibit 21.5 hereto.
In connection with the issuance of the above registration, the Company issued, on December 14, 2022, a press-release over GlobeNewswire, filed as Exhibit 99.1 hereto, under the title:
“**Bioxytran Establishes Indian Subsidiary in Preparation of Commercialization**”
On **December 14, 2022, Bioxytran (the “Company”) released an updated Corporate Presentation explaining the current state of the Company’s pharmaceutical development. The presentation is attached hereto as Exhibit 99.2.**
Folks the CEO of BIXT, OTC-QB, is run by an experienced ex-Billion dollar drug company CEO!!!
Best Drug company website in the world:
https://www.bioxytraninc.com/press-releases/bioxytran-establishes-indian-subsidiary-in-preparation-of-commercialization
BOSTON,MASSACHUSETTS, December 14, 2022 (GLOBENEWSWIRE) -- BIOXYTRAN, INC. (OTCQB: BIXT)(the “Company”), a clinical stage biotechnology company developing oral and intravenous drugs to treat COVID-19 and other viral causing diseases announced that it has established an Indian subsidiary (Pharmalectin India PrivateLimited). The purpose of the subsidiary is to launch commercial product sales of ProLectin-M should the company receive Central Drugs Standard ControlOrganization (CDSCO) approval.
The Indian manufacturing plant is an FDA approved facility capable of supporting the Indian market with a population of 1.4 billion people
And Covid is not over, just ask China, news today! :
CNN: Covid cases explode in Beijing leaving city streets empty and daily life disrupted.
https://www.cnn.com/2022/12/14/china/beijing-zero-covid-easing-streets-impact-intl-hnk-mic/index.html
Let the bid wars begin:
Why $BIXT could be worth Billions sooner than later.
https://clearcreekbio.com/pfizer-and-clear-creek-bio-to-collaborate-on-a-research-program-targeting-sars-cov-2-papain-like-protease
"Pfizer and Clear Creek Bio to Collaborate on a Research Program Targeting SARS-CoV-2 Papain-Like Protease
Agreement aims to advance discovery and development of novel papain-like protease (PLpro) inhibitors and potentially introduce a new class of oral antivirals in the fight against COVID-19
Expands Pfizer’s innovative anti-infective pipeline, complementing the company’s existing portfolio of COVID-19 products
NEW YORK & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) and Clear Creek Bio, Inc. today announced a research collaboration and exclusive license agreement to advance the discovery and development of potential inhibitors of the SARS-CoV-2 papain-like protease (PLpro) for the oral treatment of COVID-19. PLpro is an essential enzyme, which, along with the main protease (Mpro), plays an important role in viral replication. This program will expand Pfizer’s innovative anti-infective pipeline and, if successful, will complement Pfizer’s existing portfolio of COVID-19 products with direct-acting antiviral agents against different SARS-CoV-2 targets.
“COVID-19 has proven to be a devastating and highly unpredictable disease, one with the potential to remain a global health concern for years to come,” said Charlotte Allerton, Chief Scientific Officer, Anti-Infectives and Head of Medicine Design, of Pfizer. “It is critical that we try to stay ahead of the virus, continuing to advance clinical development opportunities for our current oral therapy as well as innovating through our internal programs and strategic partnerships to bring forward additional monotherapy and/or combination treatment candidates that we believe may play a role in the ongoing fight against COVID-19.”
“As COVID-19 continues to evolve, there is a significant need for oral antivirals with novel mechanisms of action,” said Vikram Sheel Kumar, M.D., Chief Executive Officer of Clear Creek Bio. “We explored the druggable SARS-CoV-2 genome and identified PLpro as a promising and untapped target. Leveraging our team’s expertise and success in bringing novel drugs from idea to approval, we internally developed highly potent PLpro inhibitors. We look forward to working with Pfizer, a global leader in antiviral development, to advance a new class of oral antivirals for COVID-19.”
Under the terms of the agreement, the two companies will work together to identify a PLpro candidate to progress into the clinic, at which time Pfizer will be solely responsible for further development and commercialization activities. Clear Creek Bio will receive an undisclosed upfront payment and will be eligible to receive additional potential milestone payments plus royalties on future product sales.
About SARS-CoV-2 PLpro
SARS-CoV-2 has two essential proteases, the main protease (Mpro) and the papain-like protease (PLpro), both required to fully process the viral polyprotein and assemble a functional replicase complex. In addition to its critical role in viral replication, the PLpro also contributes to dysregulation of host innate immunity and immune evasion.
About Pfizer: Breakthroughs That Change Patients’ Lives
At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products, including innovative medicines and vaccines. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 170 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at www.Pfizer.com. In addition, to learn more, please visit us on www.Pfizer.com and follow us on Twitter at @Pfizer and @Pfizer News, LinkedIn, YouTube and like us on Facebook at Facebook.com/Pfizer.
$BIXT is the only antiviral that eliminates 100% of Covid19 in 3 days. But it needs time to brew and age (the major drug Trials....). The first trial was 100% success, ZERO covid left after 3 days in the body. IV dosed....
.40 is the floor, and sooner or latter it will rip short to medium term.
I do not know when it will rip, but the news is spreading on LinkedIn and at $500/per person investment work shops...
In 3 years $BIXT could be a retirement stock. I have looked at the bio-chemistry on the $BIXT Carbohydrate Galectins.
In my professional opinion, They are destined to spawn an entire generation of new non toxic antivirals this decade, that can reduce the risk of lingering virus triggered cancers. It can be customized to target Every known virus, one virus at a time, like Moderna is doing with its so called vaccines, that are actually just immune booster targeting boosters, and not true Polio style vaccines.
But it is not a day trade 1-2 day stock. It is, IMO, a good ethical investment, and sooner or later a major retirement stock, IMO. But it will be a cash burner, short term...like all of these early stage firms, With the drug trials... I do suspect they may be fully funded short-medium term, and news may drop any day, so this may be a good time to buy. Support looks solid chart wise, and over sold. We will see in the next filings.
That said, news from left field of JV deals with funding, Analyst articles, and road show investment work shops can bring in new buyers, and unlike most OTC stocks, the $BIXT VP of Marketing is a seasoned expert Bio-Tech drug company analyst... Never seen that on an OTC drug start up before... Got wonder if he is waking up the Big boys that might one day co-fund major trials for other Non-covid19 viruses....
The future potential for JV funded by major drug firms, development and trials for antivirals for other viruses is a real possibility too, that could happen and give the retail share price a real boost..
I will adding to my shares going forward...
$BIXT may start singing a new tune as Season 3 of "Its not just the flu" plays out in China and the US Hospitals in early January.
$BIXT is a real sleeper, huge potential wide spectrum antiviral and blood O2 measuring tech...
https://www.cnbc.com/2022/11/30/why-long-covid-could-be-the-next-public-health-disaster.html
"Long Covid may be ‘the next public health disaster’ — with a $3.7 trillion economic impact rivaling the Great Recession"
$BIXT has bright future... Ask me why.
Good news for $BIXT
Indoor masking in L.A. could return as COVID cases spike, health officials say
by: Josh DuBose
Posted: Dec 1, 2022 / 11:12 PM PST
Updated: Dec 1, 2022 / 11:21 PM PST
Los Angeles County Director of Public Health, Dr. Barbara Ferrer, believes that if COVID-19 cases continue to rise, the county could move back into the high transmission level as soon as next week, which would mean the return of mandatory indoor masking in places like restaurants, bars and schools.
“We would be back to saying our health care system is getting stressed out, we need to slow down transmission,” Ferrer said in a Thursday press conference.
She also announced that the county was moving from low transmission levels to medium because cases and hospitalizations are rising.
L.A. County has now reported more than 2,700 cases a day or 188 cases per 100,000 residents weekly.
Health officials said the county will move into high transmission levels if reporting grows to 200 cases per 100,000 residents weekly.
“We had more people report to us positive COVID tests after they came back from Thanksgiving than we have ever had before, so there is just a lot of transmission,” Ferrer said.
Hospitals have also seen an influx of children impacted by the coronavirus.
At Children’s Hospital Los Angeles, COVID positivity jumped by 2.8% from October to November with 1 in 4 children admitted into the intensive care unit.
“I will tell you, I am definitely being pushed to the limit,” Dr. Neela Sethi, a pediatrician at Valencia Pediatrics, told KTLA’s Pedro Rivera.
Dr. Sethi said she’s seen a winter surge of COVID fill up emergency rooms and hospital beds and that’s not including children hit hard by RSV and the flu.
“Our ERs are completely overwhelmed. There are no hospital beds. ER wait times are like four to five hours. So, what we tell parents is contact us, let us help you with supportive care,” Sethi said.
This is why, according to Sethi, doctors have asked parents to just keep a close eye on their kids before bringing them in for treatment.
“If they feel like they are getting very sick overnight and struggling to breathe or they look very out of it and they’re not eating, they’re not drinking fluids, they’re not sleeping as well, then it warrants an ER visit,” Sethi said.
As of Thursday night, county public health officials are strongly recommend people wear masks indoors and urge residents to get vaccinated for protection from more severe symptoms of COVID.
Suggest a Correction
Copyright 2022 Nexstar Media Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Great news for $BIXT
FDA pulls U.S. authorization for Eli Lilly's COVID drug bebtelovimab
https://www.nasdaq.com/articles/fda-pulls-u.s.-authorization-for-eli-lillys-covid-drug-bebtelovimab
You folks need to read this. This could set a fire under $BIXT
Only 2 perfect clinical trials in the past decade
https://www.linkedin.com/pulse/mythbusting-quest-perfect-clinical-trial-michael-sheikh/
"When we at Bioxytran got our clinical trial results back I was astounded because I had never seen a perfect clinical trial in all my years in biotech. Being the diligent researcher that I am, I tried to find one but none of the search terms yielded any fruit. Then I narrowed the search looking for a 100% response rate. I found it, the other perfect clinical trial this past decade."
"Gilead Sciences purchased Pharmasset for $11.0 billion to get their at-the-time promising Phase 3 ready Hepatitis C (HCV) asset in 2011. They had a perfect 21/21 response rate for sustained virological response 12 weeks after treatment (SVR12)."
"Now, this was an open-label trial with no control, but the endpoint was SVR12 which is a proxy for the complete elimination of the virus. They enrolled 100 participants separated out by the severity of HCV; some had never had treatment and others had failed the standard of care. Across the board the results were phenomenal and two of the five cohorts had a perfect score."
"Gilead’s HCV drug is now known as Harvoni, and many refer to it as a cure for Hepatitis C as it was extremely efficacious across HCV genotypes, referred to as pan-genotypic. Harvoni (sofosbuvir) interferes with two proteins involved in the viral life cycle, preventing the replication of virions. The treatment uses sofosbuvir which is an NS5B inhibitor and a second molecule called ledipasivir which is a NS5A inhibitor. The Mechanism of Action (MOA) of these antiviral is through protease inhibition which stops the viral replication. Ledipasvir is an inhibitor of the HCV NS5A protein, which is a non-enzymatic, nonstructural protein required for viral replication. Sofosbuvir, on the other hand, is an inhibitor of the HCV NS5B RNA-dependent RNA polymerase, which helps make new RNA for the new virions."
The rest of the article is on that link on LinkedIn
$BIXT NEWS - Top-line Results from Phase 2 Trial of Galectin Antagonist on COVID-19 Patients in @medrxivpreprint - https://t.co/hEr98kHKRr #gylcotime #galectin #galectin3 #COVID19 #antivirals #longcovid @ChilesResearch @EricTopol @drbeen_medical @EnemyInAState @DrEricDing pic.twitter.com/UopYZdCx5F
— Bioxytran Inc. (@BioxytranInc) November 16, 2022
Major value inflection point for $BIXT like in 2013 when $GILD announced P2 #HCV trial and 19/19 responded. A perfectly designed clinical trial led to HCV cure. #Bioxtran #COVID19 trial 17/17 responders. Major advancement in #Galectin Science & #Glycobiology #Glycovirology pic.twitter.com/ma7T9tDTWr
— Mike Sheikh (@MikeSheikh2) November 16, 2022
The market will be paying close attention as the virus-P-demic winter round 3 that is already here, hits the hourly news....It has already started a month early...
I also want to see what it does for long Haul coivid19 and other autoimmune illnesses that might be related to low level infections... Can it eliminate the development of any new cases of Long haul covid19 that vaccines failed to do??? Can it end current long haul covid19 cases
$BIXT
https://www.bioxytraninc.com/press-releases/bioxytran-releases-positive-top-line-results-from-phase-2-trial
Bioxytran Releases Positive Top-line Results from Phase 2 Trial of ...
Complete elimination of viral load in 100% of patients at day 7 vs 6% in placebo
$BIXT in a new article
https://o.b5z.net/i/u/10253529/f/BIXT_Article.pdf
*Hell of read and dot connecting, Nobel prize....... $BIXT dot connecting history
Science behind the product:
Bioxytran has a significant subject matter expertise in the formulation of an oral form of a Galectin inhibitor. The company was able to capitalize on Dr Platt’s many years of research and recent peer reviewed articles on Galectins and COVID-19 to quickly complete the proof of concept phase. Dr Platt, who has a PhD in carbohydrate chemistry, was the first scientist to express the gene, which he named Galectin, 28 years ago.
We know that the N-terminal domain (NTD) of the coronavirus spike protein is similar from genus to genus. On the COVID-19 spike protein scientists have elucidated a galectin fold on the side of the spike that should have a binding affinity to sugar carbohydrates like ProLectin. Animal studies on influenza (needs reference) have demonstrated that inhibiting galectin-1 improves outcomes in lethal influenza models. Other animal’s models show that galectin inhibitors act as immune modulators in cancer and other diseases.
Our molecule is designed to stay in the blood and attach to the COVID-19 protein spikes. When the inhibitor binds to the spike it effectively tags the virus for elimination through the liver. Galectins are theorized to participate in the antiviral defense which starts at the initial recognition of the virus before it binds to the entry receptor all the way through the activation and amplification of the innate and adaptive responses of the immune system.
Galectins are adhesion molecules and allow neutrophils to stay prepositioned in the pulmonary capillaries for a quicker reaction in case of infection. They are also involved in the trafficking of macrophages responsible for the inflammatory cycle of the cytokine storm. Additionally, research in cancer and viruses has demonstrated that galectins form a plaque on CD-8 T-cells which inhibit the adaptive immune response. Therefore, our galectin antagonist should not only reduce the viral load of COVID-19, but also modulate the immune response by reducing the trafficking of macrophages thereby reducing the cytokine storm and returning the immune system to homeostasis. We also expect it to restore functionality to the adaptive immune system by reactivating anergic T-cells that were covered in galectin plaque.
If given early in the disease, we believe that our first drug candidate, galectin antagonist, will block viral entry and tag the virus for elimination through the liver. In theory the virus will be eliminated from the blood stream after a couple of treatments. At a later stage in the disease pathology, a more potent IV solution, ProLectin- I could restore adaptive immune function to help eradicate the virus from the body. In severe COVID-19 patients the drug, ProLectin-A, could reduce the trafficking of macrophages responsible for the cytokine storm and restore immune homeostasis. ProLectin-F is designed to treat organ damage after virus is eliminated from the system.
Galectin Antagonist is the first-in-class of inhibitors to cover a range of Galectins associated with viral replication adhesion and immune system blockage (not modulation). The N-terminal domain (NTD) of the coronavirus spike protein is similar from genus to genus. On the COVID-19 spike protein the Galectin fold on the side of the spike has a binding affinity to sugar carbohydrates like Galectin Antagonist.
Galectins are members of a family of proteins called lectins. These proteins interact with carbohydrate sugars located on the surface, in between cells, and on the Galectin fold of the spike protein. These interactions cause the cells to change behavior, including cell movement, multiplication, and other cellular functions. The interactions between lectins and their target carbohydrate sugars occur via a carbohydrate recognition domain (CRD), within the lectins. Galectins have a CRD that binds specifically to sugar molecules. They have a broad range of functions, including regulation of cell survival and adhesion, promotion of cell-to-cell interactions, growth of blood vessels, regulation of the immune response and inflammation. During viral infections Galectins are upregulated and downregulated based on the type of virus.
Bioxytran intends to develop and, through third party contracts, manufacture oxygen therapeutics. Our oxygen therapeutics are a new class of pharmaceuticals that are administered intravenously to transport oxygen to the body’s tissues. Currently there are four drug candidates to treat a stroke. Abciximab from Eli Lilly is a platelet aggregation inhibitor. Clinical trials show little advantage over placebos and could lead to dangerous side effects, including more bleeding in patients. Cerovive from AstraZeneca is a Nitrone-based neuro protectant currently in phase III clinical trials which shows no significant benefit over placebos with respect to changes in neurological impairment as measured by the national institute of health stroke scale. Candesartan, from AstraZeneca, is an angiotensin receptor blocker which was used to control blood pressure. Its efficacy in stroke patients still must be proven. Ancod from Knoll Pharmaceuticals is an anti-coagulant that acts by breaking down the fibrinogen. It increases the risk of hemorrhage similar to those associated with tPA. Using our issued patents and proprietary technology, we intend to develop and manufacture BXT-25 and similar drugs for applications including treatment of stroke conditions. Our patent position consists of 2 parts: a patent related to our co-polymer technology issued in 2009 by the United States Patent and Trademark Office expiring in February 2029 (method patent for producing modified pectins consisting of neutral sugar sequences ) and assigned to us outright by David Platt; various methods to stabilize a single hemoglobin molecule that are in the public domain; Dr. Platt did not receive any compensation from the Company in consideration of his assignment of the patent. Additionally, Bioxytran, Inc. has an exclusive license for an FDA approved technology monitoring NADH (OxySense), the control marker in the body’s conversion of Oxygen to Energy, or the energy generating chain. The technology provides a clinical end-point for measuring oxygen supply to the brain in real-time. OxySense, developed by MDX LifeSciences, Inc., provide us with a rapid, cost-effective and validated development of safe new molecules that address unmet medical needs in disease indications resulting from hypoxia. MDX LifeSciences has licensed a patent (Tissue Metabolic Score for Patient Monitoring) to Bioxytran for clinical monitoring of oxygen delivery through oxygen carriers.
AI
